Generics Bulletin is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Pricing Strategies; Reimbursement

Set Alert for Pricing Strategies and Reimbursement

Pricing Strategies

Coherus Claims Pegfilgrastim Payer Parity, But Parries Sales Queries

Coherus BioSciences is hailing US payers’ responses to its January launch of its Udenyca pegfilgrastim biosimilar; but the US-based developer sidestepped investors’ questions around sales figures.
Biosimilars Pricing Strategies

Supply Issues Drive Up Metoprolol Prices In UK

Supply issues highlighted by UK pharmacists drove up local prices for generic metoprolol in February, according to the latest figures from market researcher WaveData.

United Kingdom Pricing Strategies

Amneal Targets Up to 50 Launches, But Fears Diminishing Returns

Amneal has a solid roster of generics lined up for introduction in the US this year; but challenging market dynamics are forcing the company to reassess the commercial potential of these launches.
Launches Strategy

AAM Supports CMS' Revised Generic Drug Tiering Policies

The AAM says that it supports drug plans that automatically include generics and biosimilars on generic formulary tiers immediately after launch, in response to a CMS 2020 call letter. To support its position, the association is citing a report from Avalere that quantifies potential savings from revising Part D generics tiering.

Medicare Medicaid

Apotex Rolls Out Pegfilgrastim A Year After Canadian Approval

Apotex is rolling out its Lapelga pegfilgrastim biosimilar across Canada, almost a year after securing marketing authorization. But Mylan is seeking local reimbursement for its Fulphila alternative.
Canada Biosimilars

Candesartan Climbs As Temazepam Tumbles In UK

As candesartan tablets saw their average UK trade prices leap by as much as five times in January, temazepam tablets plummeted by almost two-thirds, according to the latest figures from market researcher WaveData.

United Kingdom Pricing Strategies
See All
UsernamePublicRestriction

Register